FDA To Review Once Rejected Regeneron/Sanofi's Blockbuster Dupixent For Type Of Inflammatory Skin Disease - Regeneron Pharmaceuticals ( NASDAQ:REGN ) , Sanofi ( NASDAQ:SNY )
On Friday, the FDA accepted for review the resubmission of the supplemental biologics license application ( sBLA ) for Regeneron Pharmaceuticals, Inc.
https://www.benzinga.com/general/biotech/24/11/42008174/fda-to-revisit-regeneron-sanofis-dupixent-for-rare-skin-disease